Oxolamine hydrochloride

Cat. No.: HY-B1717A: Data Sheet Handling Instructions
FAQs
Technical Support

Oxolamine hydrochloride (SKF-9976 hydrochloride) is an orally active antitussive. Oxolamine hydrochloride can inhibit CYP2B1/2. Oxolamine hydrochloride has anti-inflammatory effects on the respiratory organs of guinea pigs. Oxolamine hydrochloride increases the AUC of Warfarin (HY-B0687) and prolongs its terminal half-life. Oxolamine hydrochloride can be used in respiratory disease research.

For research use only. We do not sell to patients.

Oxolamine hydrochloride Chemical Structure

CAS No. : 1219-20-1

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Oxolamine hydrochloride:

Oxolamine Get quote

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Cytochrome P450 Isoform Specific Products:

View All Isoforms

CYP1 CYP2 CYP3 CYP4 CYP11 CYP17 Aromatase/CYP19A1 CYP26 CYP51 CYP1A2 CYP2D6 CYP2C9 CYP2C19 CYP3A4 CYP17A1

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[2]^[3]^[4]

CYP2B1

CYP2B2

In Vitro

Oxolamine (10 μg/mL; 24 h) hydrochloride significantly reduces the plasma protein binding of Clarithromycin (HY-17508) in fresh rat plasma^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Oxolamine (Oxolamine citrate; 10-50 mg/kg; p.o.; 3 times per day for 3 consecutive days) hydrochloride significantly increases the AUC and prolongs the terminal half-life of Warfarin (HY-B0687) in male SD rats^[3].
Oxolamine (Oxolamine citrate; 80 mg/kg body weight initially, then 53.3 mg/kg; i.p.; 11 times at 3, 6, 9, 24, 28, 32, 48, 52, 56, 72 and 76 h) hydrochloride shows a distinct anti-inflammatory action on the respiratory organs of guinea pigs^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Guinea pigs + non-bacterial inflammation of the respiratory tract model induced by inhalation of acrolein aerosol^[4]
Dosage:	80 mg/kg body weight initially, then 53.3 mg/kg
Administration:	Intraperitoneal injection, 11 times at 3, 6, 9, 24, 28, 32, 48, 52, 56, 72 and 76 h
Result:	Reduced relative lung weight. Significantly reduced inflammation levels. Protected the pulmonary parenchyma from emphysema. Showed anti-inflammatory effect superior to that of Phenylbutyrone.

Molecular Weight

281.78

Formula

C₁₄H₂₀ClN₃O

CAS No.

1219-20-1

SMILES

CCN(CC)CCC1=NC(C2=CC=CC=C2)=NO1.Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Kirilmaz L, et, al. Sustained-release dosage form of oxolamine citrate: preparation and release kinetics. J Microencapsul. Apr-Jun 1992;9(2):167-72. [Content Brief]

[2]. GIUDICI G, et, al. [On the anti-inflammatory action of oxolamine citrate]. Minerva Med. 1961 Oct 31;52:3752-5. [Content Brief]

[3]. Zhu X, et al. Gender difference in the pharmacokinetic interaction between oral warfarin and oxolamine in rats: inhibition of CYP2B1 by oxolamine in male rats. Biopharm Drug Dispos. 2007 Apr;28(3):125-33. [Content Brief]

[4]. Dahlgren S, et al. The effect of oxolamine citrate on experimentally produced inflammation in the respiratory organs. Acta Pharmacol Toxicol (Copenh). 1966;24(2):286-96. [Content Brief]